Day: February 13, 2026
Media relations:Victoire GruxTel.: +33 6 04 52 16 55victoire.grux@capgemini.com
Investor relations:Vincent BiraudTel.: +33 1 47 54 50 87vincent.biraud@capgemini.com
Full-year 2025 resultsRevenues of €22,465 million in 2025, up +1.7%
Revenue growth at constant exchange rates* of +3.4% for the full year, and +10.6% in Q4
Bookings up +3.9% at constant exchange rates to €24.4 billion with a 1.08 book-to-bill
Stable operating margin*, at 13.3% of revenues
Net profit, Group share, of €1,601 million
Basic earnings per share of €9.46, down -3.7% and normalized earnings per share of €12.95, up +5.8%
Organic free cash flow* stable at €1.95 billion
Proposed dividend of €3.40 per shareParis, February 13, 2026 – The Board of Directors of Capgemini SE, chaired by Paul Hermelin, convened on February 12, 2026 in Paris to review and adopt the accounts1...
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Written by Customer Service on . Posted in Public Companies.
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors1 Vanrafia received accelerated approval in U.S. and China for reduction of proteinuria in adults with IgAN in 2025; Novartis plans to submit for traditional approval in 20262Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia® (atrasentan). Vanrafia showed a difference of 2.39 ml/min/1.73m2 in estimated glomerular filtration rate (eGFR) change from baseline vs. placebo (2-sided p =...
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
Written by Customer Service on . Posted in Public Companies.
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the “Offering”) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less underwriting discounts and commissions.
The gross proceeds to the Company from the Offering, before deducting offering expenses payable by the Company and discounts, will be approximately $20 million. Assuming full exercise by the underwriter of its option to purchase additional...
Alkane Resources Announces Record Operating & Record Financial Results for Q2 and H1 FY2026
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
PERTH, Australia, Feb. 12, 2026 (GLOBE NEWSWIRE) — Alkane Resources Limited (“Alkane” or the “Company”) (ASX: ALK, OTC: ALKRY, TSX: ALK) is pleased to announce financial results for the six months ended 31 December 2025 (the “half” or “HY 2026”).
The Company’s condensed and consolidated interim financial result for the half, together with the Appendix 4D and Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under Alkane’s profile on www.sedarplus.ca, on the Australian Securities Exchange (“ASX”) and on Alkane’s website at www.alkres.com. All currency references in this press release are in Australian dollars except as otherwise indicated.
First Half 2026 Highlights: 1,2Record Revenues: Gold equivalent sales for the half year of 74,094 ounces generated revenues of $404 million at...
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
Written by Customer Service on . Posted in Public Companies.
BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase II/III clinical trial of novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU).
Currently, patient enrollment has been completed in the Phase III registrational clinical trial of soficitinib for the treatment of moderate to severe atopic dermatitis (AD), and in the Phase II clinical trial for the treatment of vitiligo. In addition, clinical trials of soficitinib for the treatment of psoriasis and nodular prurigo are also progressing rapidly.
Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of...
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
Written by Customer Service on . Posted in Public Companies.
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock are being sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All of the shares in the Offering are being sold by the Company. The gross proceeds to Coherus from the Offering are expected to be approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less the underwriting discounts and...
EnWave to Report First Quarter Financial Results on February 19, 2026 and Host Investor Conference Call
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) —
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announced today it will report its financial results for the first quarter ended December 31, 2025 on Thursday, February 19, 2026 after market close. The financial statements and MD&A will be available on SEDAR at www.sedarplus.ca and on the Company’s website.
The Company has scheduled a conference call to discuss the results for Q1 2026 and business outlook on Friday, February 20, 2026 at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). Brent Charleton, Chief Executive Officer and Dylan Murray, Chief Financial Officer will present EnWave’s results and host a question and answer period.
Conference Call Details:Date:
February 20, 2026Time:
7:00am PST / 10:00am ESTParticipant...
